Paradigm Biocapital Advisors LP Edgewise Therapeutics, Inc. Transaction History
Paradigm Biocapital Advisors LP
- $2.67 Billion
- Q1 2024
A detailed history of Paradigm Biocapital Advisors LP transactions in Edgewise Therapeutics, Inc. stock. As of the latest transaction made, Paradigm Biocapital Advisors LP holds 2,446,373 shares of EWTX stock, worth $44.1 Million. This represents 1.67% of its overall portfolio holdings.
Number of Shares
2,446,373Holding current value
$44.1 Million% of portfolio
1.67%Shares
1 transactions
Others Institutions Holding EWTX
# of Institutions
129Shares Held
76.3MCall Options Held
14.7KPut Options Held
14.8K-
Orbimed Advisors LLC San Diego, CA15MShares$271 Million6.17% of portfolio
-
Baker Bros. Advisors LP New York, NY5.84MShares$105 Million1.35% of portfolio
-
Black Rock Inc. New York, NY5.17MShares$93.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.02MShares$72.4 Million0.0% of portfolio
-
Viking Global Investors LP3.34MShares$60.1 Million0.23% of portfolio
About Edgewise Therapeutics, Inc.
- Ticker EWTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 63,171,700
- Market Cap $1.14B
- Description
- Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has c...